MyoD binds to Mos and inhibits the Mos/MAP kinase pathway

Activated MEK1 binds the nuclear MyoD transcriptional complex to repress transactivation

To elucidate the mechanism through which MAPK signaling regulates the MyoD family of transcription factors, we investigated the role of the signaling intermediate MEK1 in myogenesis. Transfection of activated MEK1 strongly repressed gene activation and myogenic conversion by the MyoD family. This repression was not mediated by direct phosphorylation of MyoD or by changes in MyoD stability or subcellular distribution. Deletion mapping revealed that MEK1-mediated repression required the MyoD amino-terminal transactivation domain. Moreover, activated MEK1 was nuclearly localized and bound a complex containing MyoD in a manner that is dependent on the presence of the MyoD amino terminus. Together, these data demonstrate that MEK1 signaling has a strong negative effect on MyoD activity via a novel mechanism involving binding of MEK1 to the nuclear MyoD transcriptional complex.

Regulation of scleraxis function by interaction with the bHLH protein E47

Scleraxis is a basic helix-loop-helix (bHLH) protein whose function has been postulated to be preconfigurative of sclerotomal mesenchymal patterning during early embryonic development by regulating expression of differentiation-specific genes, particularly those involved in chondrogenesis. To gain understanding of the molecular action of scleraxis we test the hypothesis that it heterodimerizes with another bHLH protein to activate gene expression. Transient coexpression of scleraxis and E47, a candidate bHLH protein, showed that scleraxis dimerizes with E47 in vivo and that this complex binds to a classic E-box DNA sequence better than either factor alone. Further, when expressed together, scleraxis and E47 synergistically enhanced transcription from a promoter containing multiple E-box binding sites.